Preclinical development of CXCR6 antagonists to target sorafenib resistance in Hepatocellular Carcinoma
针对肝细胞癌索拉非尼耐药性的 CXCR6 拮抗剂的临床前开发
基本信息
- 批准号:10630303
- 负责人:
- 金额:$ 20.96万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2022
- 资助国家:美国
- 起止时间:2022-05-27 至 2025-03-31
- 项目状态:未结题
- 来源:
- 关键词:Adverse effectsAdverse eventApoptosisAutomobile DrivingBAY 54-9085BiologicalBiological AssayBiological AvailabilityBiological MarkersCXCR6 geneCell LineCell NucleusCell ProliferationCellsChemical StructureChemoresistanceChronicClinicalCyclin D1DevelopmentDoseDown-RegulationDrug KineticsDrug TargetingDrug resistanceFDA approvedGenetic TranscriptionGrowthGrowth Factor ReceptorsHepatocyteHumanInflammationInhibition of Cell ProliferationInvadedLeadLife ExtensionLigandsLiverMAP Kinase GeneMCL1 geneMEKsMalignant Epithelial CellMalignant neoplasm of liverMeasuresMediatingMembraneMolecularMolecular BankMusNeoplasm MetastasisNexavarNuclearNuclear TranslocationOncogenicOralPI3K/AKTPathway interactionsPatientsPharmaceutical ChemistryPharmaceutical PreparationsPhenotypePhosphorylationPhosphotransferasesPrimary carcinoma of the liver cellsPrognosisProliferatingPropertyProteinsRas/RafResistanceSerious Adverse EventSignal TransductionStructure-Activity RelationshipTissuesToxic effectTyrosine Kinase InhibitorUnited States National Institutes of HealthUnresectableVascular Endothelial Growth FactorsXenograft Modeladverse event riskangiogenesisantagonistbeta cateninbeta-arrestinc-myc Geneschemokine receptorclinical biomarkersclinically relevantdesignglycogen synthase kinase 3 betahepatocellular carcinoma cell linehepatoma cellhigh throughput screeninghuman modelimmune checkpoint blockersimprovedin vivoindividualized medicineinnovationknock-downlead optimizationneoplastic cellnew therapeutic targetnovelnovel strategiesoverexpressionp38 Mitogen Activated Protein Kinasepatient responsepreclinical developmentpreclinical evaluationprogramsreceptorrecruitrepositoryresponseresponse biomarkerscreeningsmall moleculesmall molecule inhibitorspecific biomarkerssuccesssurvivintargeted agenttumor growthtumor progression
项目摘要
PROJECT SUMMARY/ABSTRACT
Sorafenib (Nexavar®) is the first FDA approved targeted drug for advanced hepatocellular
carcinoma (HCC) patients and a first-line treatment. However, it offers only a moderate life
extension in about 40% of advanced unresectable HCC patients due to low response rate, serious
adverse events and acquired resistance. Some of the cellular pathways associated with HCC
development and poor prognosis also cause resistance to sorafenib. Understanding which
pathway will have monumental impact by providing HCC specific clinical biomarkers of response
and the development of new therapeutic targets. One such pathway dysregulated in 50% of HCCs
is the activation of Wnt/β-catenin, induced by kinase cascades, notably the Ras/Raf/Mek/Erk
(targeted by sorafenib), PI3K/AKT/TOR and p38 MAPK leading to inactivation of GSK-3β kinase.
Post its escape from phosphorylation by GSK-3β and proteasomal degradation, β-catenin
accumulates in the nucleus and activates transcription of several oncogenic proteins rendering
sorafenib ineffective and promotes unchecked anti-apoptosis, cell proliferation, angiogenesis,
EMT and invasion. A novel strategy proposed by us for combating resistance to sorafenib involves
inhibiting hyperactivation of a chemokine receptor CXCR6. Signaling from CXCR6 and its ligand
CXCL16 drives resistance to sorafenib through the downstream kinases and culminates at Ser-9
phospho-GSK3β/β-catenin activation. CXCR6-knockdown in SK-Hep-1 and other hepatoma cell
lines is correlated with lower p38 activity, increased GSK3β activity, membrane sequestration of
β-catenin and downregulation of β-catenin transcriptional activity in the nucleus. We have
developed a first-in-class small molecule lead, SBI-457, that antagonizes the CXCR6 receptor, is
orally bioavailable in mice and efficacious at attenuating tumor growth in a 30-day mouse
xenograft model for advanced HCC with no adverse effects. Since CXCR6/CXCL16 are not highly
expressed in non-cancerous hepatocyte and other liver tissue, SBI-457 is expectedly non-toxic in
vivo under high dose and chronic exposure. Since there are no known clinical CXCR6 antagonists
to date, optimization of lead SBI-457 as a single agent in advanced HCC will be the first innovative
aspect of our application. A second major innovation is a combination of optimized CXCR6
antagonists with sorafenib in resistant HCC cells to understand and then overcome the major
bottleneck of chemoresistance. Hence small molecule CXCR6 antagonist leads developed in this
application have the potentially to expand the clinical use of sorafenib and other targeted agents
by re-sensitization, improved response, and lowering of the dose thereby reducing toxicity and
risk of adverse events.
项目总结/摘要
索拉非尼(Nexavar®)是第一个FDA批准的晚期肝细胞癌靶向药物
肝癌(HCC)患者和一线治疗。然而,它只提供了一个适度的生活
由于低缓解率,约40%的晚期不可切除HCC患者的严重
不良事件和获得性耐药。一些与HCC相关的细胞通路
发展和不良预后也导致对索拉非尼的耐药性。了解哪些
通过提供HCC特异性临床生物标志物,
以及新的治疗靶点的开发。其中一条通路在50%的HCC中失调
是Wnt/β-连环蛋白的激活,由激酶级联反应诱导,特别是Ras/Raf/Mek/Erk
(索拉非尼靶向)、PI 3 K/AKT/TOR和p38 MAPK导致GSK-3β激酶失活。
β-catenin逃避GSK-3β的磷酸化和蛋白酶体降解后,
在细胞核中积累并激活几种致癌蛋白的转录,
索拉非尼无效并促进不受抑制的抗凋亡、细胞增殖、血管生成
急救和入侵。我们提出的一种新的对抗索拉非尼耐药性的策略包括:
抑制趋化因子受体CXCR 6的过度活化。来自CXCR 6及其配体的信号传导
CXCL 16通过下游激酶驱动对索拉非尼的耐药性,并在Ser-9达到顶峰
磷酸-GSK 3 β/β-连环蛋白激活。SK-Hep-1和其他肝癌细胞中CXCR 6的敲低
与p38活性降低、GSK 3 β活性增加、细胞膜螯合有关。
β-catenin和β-catenin在细胞核中转录活性的下调。我们有
开发了一流的小分子铅,SBI-457,拮抗CXCR 6受体,
在小鼠中可口服生物利用,并在30天小鼠中有效减弱肿瘤生长
用于晚期HCC的异种移植物模型,没有副作用。由于CXCR 6/CXCL 16不是高度
SBI-457在非癌性肝细胞和其他肝组织中表达,但在
在高剂量和慢性暴露下。由于没有已知的临床CXCR 6拮抗剂
到目前为止,在晚期肝细胞癌中,将先导SBI-457作为单一药剂进行优化,将是第一个具有创新意义的
我们的应用方面。第二项重大创新是优化的CXCR 6
索拉非尼拮抗剂在耐药HCC细胞中的作用,以了解并克服主要的
耐药性的瓶颈。因此,小分子CXCR 6拮抗剂在这一领域得到了发展。
应用有可能扩大索拉非尼和其他靶向药物的临床应用
通过再致敏、改善反应和降低剂量,从而降低毒性,
不良事件的风险。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Siobhan Malany其他文献
Siobhan Malany的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Siobhan Malany', 18)}}的其他基金
Preclinical development of CXCR6 antagonists to target sorafenib resistance in Hepatocellular Carcinoma
针对肝细胞癌索拉非尼耐药性的 CXCR6 拮抗剂的临床前开发
- 批准号:
10435160 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
Deposition of data from ground and flight samples for sarcopenia MPS system
为肌少症 MPS 系统沉积地面和飞行样本数据
- 批准号:
10434403 - 财政年份:2018
- 资助金额:
$ 20.96万 - 项目类别:
Electrical Stimulation of Human Myocytes in Microgravity: An In Vitro Model to Evaluate Therapeutics to Counteract Muscle Wasting
微重力下人体心肌细胞的电刺激:评估对抗肌肉萎缩治疗方法的体外模型
- 批准号:
10209269 - 财政年份:2018
- 资助金额:
$ 20.96万 - 项目类别:
Electrical Stimulation of Human Myocytes in Microgravity: An In Vitro Model to Evaluate Therapeutics to Counteract Muscle Wasting
微重力下人体心肌细胞的电刺激:评估对抗肌肉萎缩治疗方法的体外模型
- 批准号:
10262954 - 财政年份:2018
- 资助金额:
$ 20.96万 - 项目类别:
Electrical Stimulation of Human Myocytes in Microgravity: An In Vitro Model to Evaluate Therapeutics to Counteract Muscle Wasting
微重力下人体心肌细胞的电刺激:评估对抗肌肉萎缩治疗方法的体外模型
- 批准号:
9788552 - 财政年份:2018
- 资助金额:
$ 20.96万 - 项目类别:
相似海外基金
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10707830 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Hospital characteristics and Adverse event Rate Measurements (HARM) Evaluated over 21 years.
医院特征和不良事件发生率测量 (HARM) 经过 21 年的评估。
- 批准号:
479728 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Operating Grants
Analysis of ECOG-ACRIN adverse event data to optimize strategies for the longitudinal assessment of tolerability in the context of evolving cancer treatment paradigms (EVOLV)
分析 ECOG-ACRIN 不良事件数据,以优化在不断发展的癌症治疗范式 (EVOLV) 背景下纵向耐受性评估的策略
- 批准号:
10884567 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
AE2Vec: Medical concept embedding and time-series analysis for automated adverse event detection
AE2Vec:用于自动不良事件检测的医学概念嵌入和时间序列分析
- 批准号:
10751964 - 财政年份:2023
- 资助金额:
$ 20.96万 - 项目类别:
Understanding the real-world adverse event risks of novel biosimilar drugs
了解新型生物仿制药的现实不良事件风险
- 批准号:
486321 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
Studentship Programs
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10676786 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
Pediatric Adverse Event Risk Reduction for High Risk Medications in Children and Adolescents: Improving Pediatric Patient Safety in Dental Practices
降低儿童和青少年高风险药物的儿科不良事件风险:提高牙科诊所中儿科患者的安全
- 批准号:
10440970 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
Improving Adverse Event Reporting on Cooperative Oncology Group Trials
改进肿瘤学合作组试验的不良事件报告
- 批准号:
10642998 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
Planar culture of gastrointestinal stem cells for screening pharmaceuticals for adverse event risk
胃肠道干细胞平面培养用于筛选药物不良事件风险
- 批准号:
10482465 - 财政年份:2022
- 资助金额:
$ 20.96万 - 项目类别:
Expanding and Scaling Two-way Texting to Reduce Unnecessary Follow-Up and Improve Adverse Event Identification Among Voluntary Medical Male Circumcision Clients in the Republic of South Africa
扩大和扩大双向短信,以减少南非共和国自愿医疗男性包皮环切术客户中不必要的后续行动并改善不良事件识别
- 批准号:
10191053 - 财政年份:2020
- 资助金额:
$ 20.96万 - 项目类别: